Product Pipeline
A number of targeted anticancer compounds are now in clinical testing through our own product programs and those of our partners. Information on the relevant subtypes of each cancer can be found in the discussion of each compound.
| Program | Indication | Pre-Clinical | Phase I | Phase II | Phase III | Approved |
|---|---|---|---|---|---|---|
IMGN901 |
Small-cell lung cancer |
 |
|
|
||
Multiple myeloma |
|
|
||||
IMGN529 |
NHL |
|
|
|||
IMGN853 |
Solid tumors |
|
|
|||
| Kadcyla™ Metastatic HER2+ breast cancer |
After Herceptin and taxane |
 |
|
|
|
|
1st line |
|
|
|
|
|
|
| Kadcyla™ Early HER2+ breast cancer |
Residual disease |
|
|
|
|
|
Neoadjuvant |
|
|
|
|
||
Adjuvant |
|
|
|
|
||
| Kadcyla™ HER2+ gastric cancer |
2nd-line metastic |
|
|
|
||
SAR3419 |
DLBCL – single agent |
 |
|
|
||
DLBCL – in combination |
|
|
|
|||
B-ALL |
|
|
|
|||
SAR650984* |
Blood cancers |
|
|
|||
SAR566658 |
Solid tumors |
|
|
|||
BT-062 |
Multiple myeloma |
 |
|
|||
BAY 94-9343 |
Solid tumors |
 |
|
|||
AMG 595 |
Gliomas |
 |
|
|||
AMG 172 |
Various cancer types |
|
|
|
ImmunoGen | |
Roche |
|
Sanofi | |
Biotest |
|
Bayer | |
Amgen |
Kadcyla™ is a trademark of Genentech.
* Naked antibody
NHL: Non-Hodgkin's lymphoma
DLBCL: Diffuse large B-cell lymphoma
B-ALL: B-cell acute lymphoblastic leukemia
Last updated May 3, 2013
